Keppra (Levetiracetam)

Levetiracetam exerts its antiepileptic effect by binding to the synaptic vesicle protein SV2A. This binding modulates the release of neurotransmitters, stabilizing neuronal firing and decreasing hyper‑excitability in the brain, which helps prevent the initiation and spread of seizure activity.

The appropriate dose of Keppra is individualized. A qualified prescriber determines the dosage based on factors such as the patient’s age, weight, renal function, seizure type, and response to therapy. Dosing recommendations are provided in the prescribing information, but the final regimen is set by the treating clinician.

Safety data for levetiracetam during pregnancy and lactation are limited. The potential risks are not fully established, so the decision to use Keppra in pregnant or nursing women should be made after a careful risk‑benefit assessment by the healthcare provider.

To request Keppra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with older antiepileptics such as carbamazepine or valproate, levetiracetam has a simpler pharmacokinetic profile, fewer drug‑enzyme interactions, and does not require routine therapeutic drug monitoring. Its side‑effect spectrum is distinct, with a lower incidence of hepatic toxicity but a higher frequency of behavioral changes in some patients.

Keppra intravenous solution should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial, as these actions could compromise stability.

Keppra is supplied as an intravenous solution that is administered by slow infusion into a vein. The infusion rate and total daily volume are determined by the prescribing clinician, who may adjust the schedule based on the patient’s clinical response and renal function.

Serious adverse reactions to Keppra include severe skin disorders such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, as well as psychiatric events like depression, suicidal thoughts, or aggressive behavior. Rare hematologic abnormalities and respiratory depression, particularly when combined with other central nervous system depressants, also warrant close monitoring.

Keppra should be avoided in individuals with a known hypersensitivity to levetiracetam or any component of the formulation. Patients with severe renal impairment may require alternative therapy or careful dose adjustment under specialist supervision. As always, the prescribing clinician assesses suitability on a case‑by‑case basis.